News & Blog
On April 18, the National Institute on Drug Abuse (NIDA) together with the Substance Abuse and Mental Health Services Administration (SAMHSA) announced research sites in four states will receive funding as part of the Helping to End Addiction Long-term (HEAL) Initiative HEALing Communities Study. Each state will engage stakeholders and researchers across 15 communities in […]
Over 2 million people in the US had chronic hepatitis C (HCV) infection during 2013- 2016, and HCV remains a leading cause of morbidity and mortality in the United States. Expanding HCV treatment in primary care would improve treatment access and follow-up but is resource intensive, requiring significant staff support. Using a budget impact analysis, […]
Every day, we hear about the staggering toll of the opioid overdose crisis. This is particularly salient in Philadelphia, which has one of the highest overdose death rates among major U.S. cities. Despite effective medications for opioid use disorder, such as buprenorphine and methadone, few people receive treatment. The ongoing challenge is to expand access to these lifesaving treatments […]
CHERISH Investigators from the University of Pennsylvania Leonard Davis Institute Zachary Meisel, Julia Mitchell, Daniel Polsky and Janet Weiner published a new study in Substance Abuse Treatment Prevention and Policy that describes how eighteen policy makers involved in the delivery of health services engage with substance use disorder (SUD) research to inform policy.
Naloxone is an opioid antagonist rescue medication that reverses the effects of an opioid overdose, and thus a critical tool to prevent fatal opioid overdoses. CHERISH Investigators Drs. Sean Murphy, Jake Morgan, and Bruce Schackman, and CHERISH staff member Philip Jeng, MS predicted pharmacy sales following conversion of naloxone to over-the-counter (OTC) in a new […]
Purdue Pharma’s 2010 reformulation of OxyContin as an abuse-resistant pill was supposed to be a breakthrough in battling the burgeoning opioid epidemic. Purdue executives and policymakers touted the reformulation as a way to dampen the supply of abusable drugs, thereby reducing opioid addiction and death. Nearly a decade later, it appears that the policy had several serious […]